Lv11
70 积分 2025-07-08 加入
An orally administered gene editing nanoparticle boosts chemo-immunotherapy in colorectal cancer
1小时前
已完结
A single gene mutation predicts response to immune checkpoint blockade in ovarian clear cell carcinoma
10天前
已完结
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial
1个月前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
1个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
1个月前
已完结
Cadonilimab, An Anti-PD-1/CTLA-4 Bi-Specific Antibody, In Combination With Chemoradiotherapy In Locally Advanced Or Isolated Metastatic Cervical Cancer: A Retrospective Study
1个月前
已关闭
187P Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
1个月前
已关闭
128TiP A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
1个月前
已关闭
PT002/#568 Cadonilimab in combination with disitamab vedotin or nab-paclitaxel in the treatment of recurrent or metastatic cervical cancer: a prospective, double-cohort, multi-center, open-label, phase II clinical study (AK001)
1个月前
已关闭
Re-Treatment With The Immune Checkpoint Inhibitor Cadonilimab In Patients With Cervical Cancer Who Progressed After Anti-PD-1 Therapy: A Real-World Study
2个月前
已关闭
皖公网安备34019202002308
